跳至主要内容
临床试验/NCT05013957
NCT05013957已完成不适用

Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2022年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
32
试验地点
1
主要终点
Methylation-based classification of NEN samples

研究概览

简要总结

Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. The currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA represent a new, promising approach.

The aim of this project is therefore to improve the diagnostic and prognostic evaluation of neuroendocrine neoplasms by means of methylation analysis of the tumor DNA. On the one hand, existing tumor samples from the biobank of Basel University Hospital are evaluated, on the other hand, patients who are undergoing an operation will be prospectively inquired

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • neuroendocrine tumor

排除标准

  • insufficient amount or quality of neuroendocrine tumor sample

结局指标

主要结局

Methylation-based classification of NEN samples

时间窗: 3 years

NEN samples will be classified according to methylation analysis

次要结局

未报告次要终点

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验